Historic Time in Treatment of CF as Promising Drugs Reach Phase 3 Trials
More than 4,600 cystic fibrosis researchers and health care professionals gathered Oct. 27 - 29 in Orlando for the 30th annual North American Cystic Fibrosis Conference. Recordings of the three plenary sessions are now available online.
We asked three people in the CF community to share their favorite sessions from this year’s North American Cystic Fibrosis Conference.
As someone who does not qualify for Trikafta®, I took particular interest in the first plenary of the North American Cystic Fibrosis Conference, which discussed potential treatments for people with nonsense and rare mutations. I learned that researchers are exploring a variety of options, and some early research has shown promising results.
While I’ve had the incredible opportunity to participate in clinical trials for cystic fibrosis, my nonsense mutations mean I can’t benefit from modulators. I was inspired by the North American Cystic Fibrosis Conference’s second plenary session, which discussed how we can evolve clinical trials to develop treatments for all people with CF.
The third plenary at this year’s North American Cystic Fibrosis Conference focused on the changing needs of the CF population that are compelling an evolution in CF care. As a person with CF, this evolution in care directly affects me as I face the challenges of living longer with this disease.